- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
HOYA clear optic IOLs gain FDA approval
HOYA Surgical Optics Inc. announced it received FDA approval for the commercial distribution of two models of clear foldable hydrophobic acrylic-optic aspheric IOLs, the iSymm (Model FC-60AD) and the preloaded iSert (Model PC-60AD), in the United States.
Chicago-HOYA Surgical Optics Inc. announced it received FDA approval for the commercial distribution of two models of clear foldable hydrophobic acrylic-optic aspheric IOLs, the iSymm (Model FC-60AD) and the preloaded iSert (Model PC-60AD), in the United States.
These lenses are an important addition to HOYA’s line of foldable and preloaded IOLs available with an optimized aspheric design, according to a prepared statement from the company.
“HOYA Surgical Optics remains strongly committed to our U.S. customers and delivering on this new direction in refractive cataract surgery,” said Jake Vander Zanden, president, Americas. “Our COMPLETE SYSTEM uses the HOYA iTrace surgical workstation with advanced wavefront diagnostics to assist surgeons in the proper selection of an IOL, based on the patient’s specific optical system.”
For more articles in this issue of Ophthalmology Times Conference Briefclick here.
